Correspondence 1889 with cyclin D1. The cells were negative for anti-CD 10, 23, LMP1 and in situ hybridisation for Epstein-Barr virus RNA (EBERs) was also negative. A diagnosis of blastic variant of mantle cell lymphoma was made.
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To our knowledge, the blastic variant of mantle cell lymphoma has not been previously described in the setting of HIV. As is common with HIV-related lymphoma, our first case was positive for LMP1, whereas the second case which was not related to HIV, was negative for LMP1 and EBERs.
The second patient was significantly immunosuppressed over a 20-year period for treatment of autoimmune disease. There is known to be an increased incidence of non-Hodgkin's lymphoma in autoimmune diseases, including Sjogren's syndrome, rheumatoid arthrits and systemic lupus erythematosis, but again the blastic variant of mantle cell lymphoma has not been reported. [3] [4] [5] Both of our cases were females less than 60 years old, whereas the majority of cases Leukemia (2002) 16, 1889. doi:10.1038/sj.leu.2402628
Reply to Munro et al

TO THE EDITOR
We thank Munro et al for their interesting correspondence about blastic variant of mantle cell lymphoma (MCL) occurring in immunocompromised patients. In our series, none of the 33 patients were found to have immunosuppression on diagnosis (ie none of them was HIV-positive or previously received cytostatic or immunosuppressive drugs or had underlying autoimmune diseases). Since our report on 187 MCL patients, we have observed 15 additional cases, two with a blastic variant form. 1 None of these was immunocompromised on diagnosis. We fully agree with Munro et al on the utility of performing complete immunophenotyping (particularly using CD5/CD23 MoAbs) and looking for cyclin D1 overexpression in high-grade B cell lymphoma even those occurring in immunocompromised patients. It is possible that with increasing use of immunohistochemistry for cyclin D1 and CD5 and molecular analysis for the t(11;14) translocation, more cases of the blastic variant of mantle cell lymphoma will be identified and immunosuppression as a risk factor may become more clearly defined.
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